Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Short Interest Update

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 235,100 shares, a drop of 20.5% from the August 31st total of 295,900 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average trading volume of 289,100 shares, the short-interest ratio is presently 0.8 days.

Petros Pharmaceuticals Trading Up 4.2 %

Shares of Petros Pharmaceuticals stock traded up $0.01 during trading on Friday, hitting $0.35. The stock had a trading volume of 33,841 shares, compared to its average volume of 577,828. The stock has a 50 day simple moving average of $0.36 and a 200 day simple moving average of $0.61. The company has a market capitalization of $2.45 million, a PE ratio of -0.04 and a beta of 2.09. The company has a quick ratio of 1.26, a current ratio of 1.40 and a debt-to-equity ratio of 0.71. Petros Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $2.27.

Petros Pharmaceuticals (NASDAQ:PTPI) last released its earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share for the quarter. The firm had revenue of $1.42 million for the quarter.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).